Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate

Negative

AI Analysis

Summary

Caribou Biotherapeutics is halting its CAR-T cell therapy program for lymphoma and laying off staff due to inability to secure funding, despite having a late-stage development candidate ready for testing. The company will pursue strategic alternatives instead.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Company halting CAR-T development program and laying off staff due to inability to secure funding

Importance:7/10

Sentiment:

-0.85

CAR-T therapyallogeneic cell therapyprogram haltlayoffsfunding challengeslymphoma

Related Companies

$CRBU

Read the original article

Published by BioPharma Dive on October 7, 2026 3:37 PM

Read Original